Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)

NCT02504372 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1177

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: Pembrolizumab
OTHER: Placebo

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]
[object Object]